Patents Represented by Attorney, Agent or Law Firm Suzanne L. Biggs
  • Patent number: 6818616
    Abstract: Compositions enriched for Neutrophil Inhibitory Factor which inhibit neutrophil activity including adhesion to vascular endothelial cells are provided. Also provided are recombinant Neutrophil Inhibitory Factors which also which inhibit neutrophil activity. Such compositions may comprise a glycoprotein isolated from nematodes. These compositions and recombinant Neutrophil Inhibitory Factors are useful in the therapy of conditions which involve abnormal or undesired inflammatory responses.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: November 16, 2004
    Assignee: Corvas International, Inc.
    Inventors: Matthew Moyle, David L. Foster, George P. Vlasuk
  • Patent number: 6777431
    Abstract: The present invention provides compounds which have a pyrazinone or pyridinone ring at P3 and an optionally substituted heteroaryl group at P1. These compounds have biological activity as active and potent inhibitors of thrombin. Their pharmaceutically acceptable salts, pharmaceutical compositions thereof and methods of using these compounds and pharmaceutical compositions comprising these compounds as therapeutic agents for treatment of disease states in mammals which are characterized by abnormal thrombosis are also described.
    Type: Grant
    Filed: July 13, 2001
    Date of Patent: August 17, 2004
    Assignee: Corvas International, Inc.
    Inventors: Daniel Vanna Siev, Joseph Edward Semple, Mallareddy Komandla, John Eugene Reiner, Scott Jeffrey Kemp
  • Patent number: 6756211
    Abstract: Compositions enriched for Neutrophil Inhibitory Factor which inhibit neutrophil activity including adhesion to vascular endothelial cells are provided. Such compositions may comprise a glycoprotein isolated from nematodes. These compositions are useful in the therapy of conditions which involve abnormal or undesired inflammatory responses.
    Type: Grant
    Filed: May 11, 1993
    Date of Patent: June 29, 2004
    Assignee: Corvas International, Inc.
    Inventors: Matthew Moyle, David L. Foster, George P. Vlasuk
  • Patent number: 6586405
    Abstract: Novel compounds having activity as non-covalent inhibitors of urokinase and having activity in reducing or inhibiting blood vessel formation are provided. These compounds have P1 a group having an amidino or guanidino moiety or derivative thereof. These compounds are useful in vitro for monitoring plasminogen activator levels and in vivo in treatment of conditions which are ameliorated by inhibition of or decreased activity of urokinase and in treating pathologic conditions wherein blood vessel formation is related to a pathologic condition.
    Type: Grant
    Filed: December 7, 2000
    Date of Patent: July 1, 2003
    Assignee: Corvas International, Inc.
    Inventors: Joseph Edward Semple, Michael I. Weinhouse, Odile Esther Levy, Edwin L. Madison, Amir P. Tamiz
  • Patent number: 6576613
    Abstract: Novel inhibitors of urokinase are provided which have an arginine or arginine mimic aldehyde or an arginine ketoamide group at P1. These compounds are useful in vitro for monitoring plasminogen activator levels and in vivo in treatment of conditions which are ameliorated by inhibition of or decreased activity of urokinase.
    Type: Grant
    Filed: July 24, 1998
    Date of Patent: June 10, 2003
    Assignee: Corvas International, Inc.
    Inventors: Terence K. Brunck, Susan Y. Tamura, Edwin L. Madison
  • Patent number: 6573292
    Abstract: Methods for the treatment of Chronic Lymphocytic Leukemia and B-cell and T-cell lymphomas are provided. These methods comprise administering to a patient in need of treatment an effective amount of certain indole and carbazole compounds, such as etodolac.
    Type: Grant
    Filed: July 6, 2001
    Date of Patent: June 3, 2003
    Assignee: Salmedix, Inc.
    Inventor: Francis A. Nardella
  • Patent number: 6541467
    Abstract: The present invention provides compounds having a lactam ring at P3 and at P1 have a six-membered heterocyclic ring having two ring nitrogen ring atoms and the remainder of the ring atoms carbon atoms. These compounds have biological activity as active and potent inhibitors of thrombin. Their pharmaceutically acceptable salts, pharmaceutical compositions thereof and methods of using these compounds and pharmaceutical compositions comprising these compounds as therapeutic agents for treatment of disease states in mammals which are characterized by abnormal thrombosis are also described.
    Type: Grant
    Filed: April 14, 2000
    Date of Patent: April 1, 2003
    Assignee: Corvas International, Inc.
    Inventors: Jonathan Zhanqi Ho, Joseph Edward Semple
  • Patent number: 6534629
    Abstract: Proteins which have activity as anticoagulants and/or serine protease inhibitors and have at least one NAP domain and are described. Certain of these proteins have factor Xa inhibitory activity and others have activity as inhibitors of factor VIIa/TF. These proteins can be isolated from natural sources as nematodes, chemically synthesized or made by recombinant methods using various DNA expression systems.
    Type: Grant
    Filed: February 12, 1999
    Date of Patent: March 18, 2003
    Assignee: Corvas International, Inc.
    Inventors: George Phillip Vlasuk, Patrick Eric Hugo Stanssens, Joris Hilda Lieven Messens, Marc Josef Lauwereys, Yves Rene LaRoche, Laurent Stephane Jespers, Yannick Georges Jozef Gansemans, Matthew Moyle, Peter W. Bergum
  • Patent number: 6506760
    Abstract: Compounds of the invention are active as inhibitors of Thrombin and are useful in treating disease states in mammals which are characterized by abnormal thrombosis and have the following structure: as described herein.
    Type: Grant
    Filed: April 14, 2000
    Date of Patent: January 14, 2003
    Assignee: Corvas International, Inc.
    Inventors: Gian Luca Araldi, Joseph Edward Semple
  • Patent number: 6506754
    Abstract: The present invention provides compounds which have a pyrazinone or pyridinone ring at P3 and which feature a six member heterocyclic ring having two ring nitrogen atoms and the remainder of the ring atoms carbon atoms at P1. These compounds have biological activity as active and potent inhibitors of thrombin. Their pharmaceutically acceptable salts, pharmaceutical compositions thereof and methods of using these compounds and pharmaceutical compositions comprising these compounds as therapeutic agents for treatment of disease states in mammals which are characterized by abnormal thrombosis are also described.
    Type: Grant
    Filed: April 14, 2000
    Date of Patent: January 14, 2003
    Assignee: Corvas International, Inc.
    Inventors: Daniel Vanna Siev, Gian Luca Araldi, Jonathan Zhanqi Ho, John Eugene Reiner, Joseph Edward Semple
  • Patent number: 6506761
    Abstract: Compound of the invention are active as inhibitors of Thrombin and are useful in treating disease states in mammals which are characterized by abnormal thrombosis and have the following structure: as described herein.
    Type: Grant
    Filed: April 14, 2000
    Date of Patent: January 14, 2003
    Assignee: Corvas International, Inc.
    Inventors: Gian Luca Araldi, Joseph Edward Semple
  • Patent number: 6432922
    Abstract: Novel compounds having activity inhibitors of urokinase and in reducing or inhibiting blood vessel formation are provided. These compounds have an arginine or arginine mimic aldehyde or an arginine ketoamide group at P1. These compounds are useful in vitro for monitoring plasminogen activator levels and in vivo in treatment of conditions which are ameliorated by inhibition of or decreased activity of urokinase and in treating pathologic conditions wherein blood vessel formation is related to a pathologic condition.
    Type: Grant
    Filed: July 22, 1999
    Date of Patent: August 13, 2002
    Assignee: Corvas International, Inc.
    Inventors: Terence K. Brunck, Susan Y. Tamura